

Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details

Unit NAV RM2.9229

Fund Size RM62.3 million

Inception Date 1 April 2005


Management Fee 1.50% per annum

Top 10 Holdings

Dufu Technology	8.9%
Pentamaster	8.7%
Frontken	8.4%
Duopharma Biotech	4.9%
Carimin Petroleum	4.4%
Power Root	4.3%
OCK Group	4.0%
KNM Group	3.3%
Cypark Resources	3.3%
Formosa Prosonic	3.2%

Data as at 31 January 2020

Cumulative Performance Since Inception as at 31 January 2020




Performance Table as at 31 January 2020

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	-2.8%	-0.1%	11.5%	-2.8%	28.1%	31.5%	60.6%	515.3%
Benchmark	-3.8%	-3.7%	-6.0%	-3.8%	-6.6%	-7.2%	-11.3%	85.7%

- Benchmark: FTSE Bursa Malaysia Emas Index
- Source: Bloomberg & Gibraltar BSN Life Bhd

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 31 January 2020



Source: UOBAM



Manager's Comment

For January 2020, the Fund's NAV/unit decreased by 2.8%, outperformed the FBM EMAS which decreased by 3.8% due to the Fund's overweight position in technology. Technology stocks outperformed in anticipation of improved earnings on reduced US-China trade war risk and ramping up of semiconductor components for 5G network technology rollout.

Global equities were mixed in January. The year started off on a positive note with the successful signing of the phase one trade deal between the US and China in mid-January. However, market jitters emerged around the Chinese New Year period due to the coronavirus outbreak.

FBM KLCI index dropped 3.6% to close at 1,531 points. The broader market FBM Emas Index declined by 3.8% to close at 10,890 points while the FBM Small Cap Index underperformed by 6.3% to close at 13,274 points. Most Asian markets were in negative territory with Hong Kong and Taiwan being the major laggards.

In other development, Bank Negara Malaysia surprised the market with an earlier-than-expected 25bps cut in the overnight policy rate (OPR).

Brent crude oil declined 11.9% and CPO future decreased 14.7%. Meanwhile, the Ringgit weakened by 0.2% against the US Dollar.

Moving forward, we expect weakness in the local bourse due to the COVID-19 outbreak. While it is too early to assess the impact to Malaysia's economy, it could be significant if the outbreak widens and persists. Sectors which could be directly hit are tourism, retail, and transportation. Using the 2003 SARS outbreak as a basis for comparison, equities bottomed when the number of cases peaked. However, when cases started to decline, equity markets staged a V-shaped rebound. We would monitor for signs of the market bottoming and take opportunity of the market weakness to buy stocks with strong fundamentals.

For Internal Use Only

Disclaimer

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at www.gibraltarsbn.com for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.